📈 Live Market Tracking
Every NSE and BSE corporate filing, read and explained by AI within minutes — impact, key figures, short/long-term view and what to watch.
Live · AI analyzer runs every 5 min (07:00–23:55 IST)
Latest filing: 2026-08-22 13:45
12 analysed today
12
Today
136,532
All-time analysed
40,460
Positive
6,317
Negative
81,819
Neutral
7,868
Watch
📊 Last 7 days — analysed filings by sentiment
Note: These are AI-generated, educational summaries of public NSE
filings — grounded in each document, but not investment advice and possibly incomplete.
Verify against the original filing and consult a SEBI-registered adviser before acting.
16 announcements match the current filters (relevance ≥ 5).
Heranba Approves Up to ₹25 Cr Capital Infusion in Subsidiary Mikusu India via Rights Issue
Heranba Industries' Board of Directors approved an additional investment of up to ₹25 Crore in its wholly owned subsidiary, Mikusu India Private Limited, via a rights issue. Mikusu India, engaged in trading agrochemical products, reported a turnover of ₹182.68 Crore in FY26, up from ₹152.40 Crore in FY25 and ₹92.91 Crore in FY24. The capital infusion represents ~3.7% of Heranba's current market capitalization (₹668 Crore) and is intended to support Mikusu's operational and growth needs without changing the 100% shareholding structure.
Confidence: HIGH
What changedHeranba is injecting up to ₹25 Crore of fresh equity into its wholly owned trading arm, Mikusu India.
Why it mattersProvides working capital to support Mikusu India's expanding trading operations, which have scaled from ₹92.91 Crore to ₹182.68 Crore turnover over the last two fiscal years.
Proposed Investment: ₹25 CroresMikusu FY26 Turnover: ₹182.68 CroresMikusu FY25 Turnover: ₹152.40 CroresMikusu FY24 Turnover: ₹92.91 CroresInvestment vs Market Cap: ~3.7%Post-issue Shareholding: 100%
📅 Short termNeutral impact as the transaction is an internal capital reallocation between the parent and its 100% subsidiary.
📈 Long termSupports growth in the agrochemical trading vertical, though overall consolidated profitability remains reliant on core technicals and manufacturing asset utilization.
⚠ Risk flags
- Consolidated working capital strain given Heranba's net loss in FY26 and existing debt of ₹482 Cr.
Key Highlights
Approved equity capital infusion of up to ₹25 Crore in wholly owned subsidiary Mikusu India Private Limited via rights issue.
Mikusu India's turnover grew to ₹182.68 Crore in FY26 from ₹152.40 Crore in FY25 and ₹92.91 Crore in FY24.
The transaction will be completed in cash with no change in 100% ownership or control.
Investment of ₹25 Crore equals ~3.7% of Heranba's market cap and ~2.6% of net worth.
👀 What to Watch
Track the deployment timeline of the ₹25 Crore infusion and monitor if Mikusu's trading volume growth improves consolidated operating margins in subsequent quarterly results.
Heranba Q1 Standalone PAT at ₹9.46 Cr (Down 57% YoY); Approves ₹25 Cr Subsidiary Infusion
Heranba Industries reported standalone revenue of ₹364.99 crore for the quarter ended June 30, 2026, declining 25.5% YoY from ₹489.84 crore but recovering 3.3% QoQ. Standalone PAT fell 57.0% YoY to ₹9.46 crore compared to ₹22.02 crore in Q1 FY26, though it rebounded into profit from a net loss of ₹12.50 crore in Q4 FY26. Diluted EPS stood at ₹2.37 versus ₹5.50 YoY. Additionally, the Board approved an equity investment of up to ₹25 crore in its wholly owned subsidiary, Mikusu India Private Limited, through a rights issue.
Confidence: HIGH
What changedReported Q1 standalone results marking a sequential return to profitability despite YoY contraction, and approved a ₹25 crore capital infusion in subsidiary Mikusu India.
Why it mattersShows operational stabilization after Q4 FY26 losses, though ongoing global agrochemical pricing and volume pressures continue to keep margins compressed relative to historic levels.
Revenue from Operations (Q1): ₹364.99 crNet Profit (Q1): ₹9.46 crSubsidiary Investment: ₹25.00 crInvestment vs Net Worth: ~2.6%
📅 Short termSequential profit recovery from Q4 losses may offer near-term relief, though the substantial YoY decline reflects persistent sector-wide headwinds.
📈 Long termLong-term recovery relies on demand stabilization in export technicals, operating leverage from recently commissioned capex, and commercial execution in subsidiaries.
⚠ Risk flags
- Continued pricing and demand pressure in the agrochemical export technicals segment
- Asset underutilization impacting returns on recent capex additions
Key Highlights
Standalone revenue from operations stood at ₹364.99 Cr, down 25.5% YoY from ₹489.84 Cr
Net profit after tax reached ₹9.46 Cr compared to ₹22.02 Cr in Q1 FY26 and a loss of ₹12.50 Cr in Q4 FY26
Basic and diluted EPS reported at ₹2.37 for the quarter (vs ₹5.50 in Q1 FY26)
Approved rights issue investment of up to ₹25 Cr in wholly owned subsidiary Mikusu India Private Limited
👀 What to Watch
Track capacity ramp-up and export realization trends across the Saykha and Sarigam plants, alongside deployment and return metrics from the ₹25 crore subsidiary investment.
Heranba Settles IBC Dispute; NCLT Allows Withdrawal of Insolvency Application
Heranba Industries has successfully settled its dispute with Haresh Petrochem Private Limited, which had previously filed an insolvency application under Section 9 of the IBC. The National Company Law Tribunal (NCLT), Ahmedabad, passed an order on June 08, 2026, allowing the withdrawal of the application following the settlement. As a result, no Corporate Insolvency Resolution Process (CIRP) has been initiated against the company. This resolution eliminates a significant legal risk that could have impacted the company's operations and credit standing.
Key Highlights
NCLT Ahmedabad permitted the withdrawal of the Section 9 IBC application filed by Haresh Petrochem Private Limited.
The matter was settled out of court between Heranba Industries and the applicant.
No Corporate Insolvency Resolution Process (CIRP) was initiated against the company.
The final order disposing of the application was dated June 08, 2026.
The company confirmed there is no material adverse impact on its operations following this order.
👀 What to Watch
Investors can breathe a sigh of relief as the threat of insolvency proceedings has been removed. Continue to monitor the company's cash flow management to ensure no further payment defaults occur.
Heranba FY26 Revenue Up 17% to ₹1,756 Cr; Q4 Net Loss Widens to ₹12.5 Cr
Heranba Industries reported a mixed set of results for FY26, with annual revenue growing 17.4% YoY to ₹1,755.55 crore, though annual net profit declined by 5.8% to ₹50.87 crore. The fourth quarter (Q4FY26) was particularly weak, with revenue falling 10.6% YoY and net losses widening to ₹12.50 crore from a loss of ₹5.28 crore in the previous year's quarter. Financial health concerns have emerged as short-term borrowings doubled to ₹458.05 crore and operating cash flow turned significantly negative at ₹(203.92) crore. Consequently, the board has skipped recommending a dividend for the year.
Key Highlights
Full-year FY26 revenue increased 17.4% YoY to ₹1,755.55 crore, but Net Profit fell 5.8% to ₹50.87 crore.
Q4 FY26 standalone net loss widened to ₹12.50 crore compared to a loss of ₹5.28 crore in Q4 FY25.
Short-term borrowings surged to ₹458.05 crore as of March 31, 2026, up from ₹230.46 crore in the previous year.
Net cash flow from operating activities deteriorated to negative ₹203.92 crore from a positive ₹136.71 crore in FY25.
The Board of Directors did not recommend any dividend for the financial year 2025-26.
👀 What to Watch
Investors should exercise caution as the company faces margin pressure from rising raw material costs and a significant increase in debt. The transition to negative operating cash flow and the decision to skip dividends suggest liquidity tightness that warrants close monitoring.
Heranba Shareholders Approve Director Appointments with 99.99% Majority
Heranba Industries Limited has successfully passed two special resolutions via postal ballot with near-unanimous shareholder support. The resolutions involved the appointment of Mr. Omprakash Singh as a Non-Executive Independent Director for five years and Mr. Roshan R Shetty as a Whole Time Director. The voting saw a total turnout of 75.24% of outstanding shares, with both resolutions receiving 99.99% approval from the voting members. This indicates strong alignment between the management and the shareholder base, including promoters and public institutions.
Key Highlights
Appointment of Mr. Omprakash Singh as Independent Director approved with 30,105,046 votes in favor (99.99%).
Appointment of Mr. Roshan R Shetty as Executive Director approved with 30,104,959 votes in favor (99.99%).
Total voter turnout represented 75.24% of the company's total outstanding shares.
Promoter and Promoter Group voted 100% in favor of both resolutions, representing 29,987,138 shares.
The postal ballot process was conducted between April 22, 2026, and May 21, 2026.
👀 What to Watch
Investors should take note of the stable leadership and strong shareholder mandate, which supports management continuity. No immediate portfolio action is required as these are standard governance appointments.
NCLT Dismisses Insolvency Application Against Heranba Industries Subsidiary
The National Company Law Tribunal (NCLT), Mumbai Bench, has dismissed an insolvency application filed under Section 9 of the IBC against Heranba Organics Private Limited, a wholly-owned subsidiary of Heranba Industries. The application, filed by Haresh Petrochem Private Limited, was rejected because the principal operational debt fell below the mandatory threshold limit after excluding interest components. This ruling ensures that no Corporate Insolvency Resolution Process (CIRP) will be initiated against the subsidiary, removing a potential legal risk for the parent company.
Key Highlights
NCLT Mumbai Bench-VI dismissed the Section 9 IBC application on May 12, 2026
The application was filed by Haresh Petrochem Private Limited against wholly-owned subsidiary Heranba Organics Private Limited
Dismissal was based on the debt falling below the threshold limit prescribed under Section 4 of the IBC
No Corporate Insolvency Resolution Process (CIRP) has been initiated against the subsidiary
Company confirms no material adverse impact on Heranba Industries Limited following this order
👀 What to Watch
Investors can take comfort in the dismissal of this insolvency petition, which removes a legal overhang on the company's subsidiary. No further action is required as the operational risk from this specific litigation has been mitigated.
Heranba Converts ₹450 Cr Inter-Corporate Deposits into OFCDs in Subsidiary HOPL
Heranba Industries has completed the conversion of ₹450 crore worth of unsecured Inter-Corporate Deposits (ICDs) into Optionally Fully Convertible Debentures (OFCDs) in its wholly-owned subsidiary, Heranba Organics Private Limited (HOPL). This internal debt restructuring involves the allotment of 45 crore OFCDs at ₹10 each and does not involve any fresh cash outflow. The subsidiary, HOPL, has shown significant growth with a turnover of ₹220.58 crore in FY 2024-25 compared to just ₹0.27 crore in the previous year. The parent company continues to hold 100% equity and control in the subsidiary.
Key Highlights
Conversion of ₹450 crore existing unsecured ICDs into 45,00,00,000 1% OFCDs at par
Subsidiary HOPL reported a turnover of ₹220.58 crore for FY 2024-25, up from ₹0.27 crore in FY 2023-24
The transaction is an internal debt restructuring with no fresh cash outflow from Heranba Industries
Heranba Industries maintains 100% shareholding and control of HOPL post-conversion
The conversion was executed on an arm's length basis as per SEBI regulations
👀 What to Watch
Investors should view this as a routine internal financial cleanup that formalizes the debt structure of the subsidiary. The rapid revenue growth in the HOPL subsidiary is a positive operational sign to monitor in future consolidated earnings.
Heranba Industries to Convert ₹450 Cr ICDs into OFCDs of Subsidiary Heranba Organics
Heranba Industries has approved the conversion of ₹450 crore in existing unsecured Inter-Corporate Deposits (ICDs) provided to its wholly-owned subsidiary, Heranba Organics Private Limited (HOPL), into Optionally Fully Convertible Debentures (OFCDs). This internal restructuring involves the issuance of 45 crore OFCDs at a face value of ₹10 each on a private placement basis. The transaction does not involve any fresh cash outflow and is designed to restructure the debt profile of the subsidiary. HOPL, which operates in the agrochemicals sector, showed significant growth with a turnover of ₹220.58 crore in FY 2024-25 compared to just ₹0.27 crore in the previous year.
Key Highlights
Conversion of ₹450 crore unsecured ICDs into 45,00,00,000 OFCDs at a face value of ₹10 each
Target entity Heranba Organics Private Limited (HOPL) is a 100% material unlisted subsidiary
HOPL reported a substantial turnover increase to ₹220.58 crore in FY 2024-25 from ₹0.27 crore in FY 2023-24
The restructuring involves no fresh cash outflow and maintains 100% parent control
The transaction was conducted on an arm's-length basis as part of internal debt management
👀 What to Watch
As this is an internal financial restructuring with no cash outflow, it has no immediate impact on consolidated valuations. Investors should focus on the rapid scaling of the subsidiary HOPL as a potential future growth driver for the parent company.
Heranba Industries to Convert ₹450 Cr Subsidiary Loan into 10-Year Convertible Debentures
Heranba Industries has approved the conversion of ₹450 crore in Inter-Corporate Deposits (ICDs) provided to its wholly-owned subsidiary, Heranba Organics Private Limited, into Optionally Fully Convertible Debentures (OFCDs). This restructuring formalizes the internal funding into a long-term instrument with a 10-year tenure and a nominal 1% annual interest rate. The OFCDs provide the parent company the option to convert the debt into equity shares of the subsidiary in the future. Since this is an internal transaction between a parent and its 100% subsidiary, it has no immediate impact on consolidated financial performance.
Key Highlights
Conversion of ₹450 crore existing Inter-Corporate Deposits into Optionally Fully Convertible Debentures (OFCDs).
The new debentures carry a long-term tenure of 10 years.
The coupon rate is set at a nominal 1% per annum, significantly lower than market debt rates.
The transaction is aimed at restructuring existing inter-company funding on an arm's length basis.
👀 What to Watch
No immediate action is required as this is a balance sheet reclassification of existing internal funds. Investors should monitor the operational progress of the subsidiary, Heranba Organics, to evaluate the long-term value of the conversion option.
Heranba Launches New Crop Nutrition Products; Targets ₹2,500 Cr Revenue in FY26
Heranba Industries has strategically entered the high-growth crop nutrition segment with the launch of two new products, Fentaamine and MycoHil, developed in collaboration with an American MNC. The company has set an ambitious total revenue target of ₹2,500 crore for the current fiscal year, supported by its entry into this segment which is growing at a 15% CAGR. Expansion plans also include establishing a subsidiary in Dubai to penetrate Middle Eastern and African markets. This diversification leverages Heranba's seven manufacturing facilities and aims to move beyond its core synthetic pyrethroids business.
Key Highlights
Launched Fentaamine (bio-stimulant) and MycoHil (bio-fertilizer) in collaboration with a leading American MNC
Set an ambitious total revenue target of ₹2,500 crore for the current fiscal year
Targeting the crop nutrition segment which is growing at a CAGR of over 15% globally and in India
Plans to establish a subsidiary in Dubai to strengthen presence across 80+ countries
Leveraging 7 world-class manufacturing facilities to scale up CMO operations and brand equity
👀 What to Watch
Investors should monitor the company's ability to meet the ₹2,500 crore revenue guidance and the market's response to the new bio-stimulant products. The diversification into high-growth segments and global expansion via a Dubai subsidiary are strong positive indicators for long-term value.
Heranba Appoints Omprakash Singh and Roshan Shetty to Board for 5-Year Terms
Heranba Industries has announced the appointment of Mr. Omprakash S. Singh as a Non-Executive Independent Director and Mr. Roshan R. Shetty as an Executive Director, both for five-year terms starting April 1, 2026. Mr. Singh brings over 40 years of experience in legal, secretarial, and SEBI compliance matters. Mr. Roshan Shetty, a Chemical Engineer from Georgia Tech and son of the Managing Director, holds a 1.59% stake and will focus on process design and engineering. These appointments are subject to shareholder approval and aim to strengthen the company's governance and technical leadership.
Key Highlights
Mr. Omprakash S. Singh appointed as Independent Director for a 5-year term with 40+ years of legal experience.
Mr. Roshan R. Shetty appointed as Executive Director for a 5-year term starting April 2026.
Mr. Roshan Shetty holds a 1.59% equity stake and is the son of the current Managing Director.
New Executive Director brings technical expertise from Georgia Institute of Technology in Chemical Engineering.
Appointments are aimed at improving operational efficiency and ensuring robust regulatory compliance.
👀 What to Watch
Investors should monitor if the technical expertise of the new Executive Director leads to improved R&D or operational margins. No immediate action is required as these are standard leadership transitions and succession planning.
Heranba Industries Faces ₹2.63 Crore Insolvency Petition Over Quality Dispute
Haresh Petrochem Private Limited has filed an insolvency application against Heranba Industries Limited under the IBC for a claim of approximately ₹2.63 Crores. Heranba has clarified that the payment was withheld due to quality issues with the goods supplied and is actively working to resolve the matter. The company expects to settle the dispute amicably outside of the NCLT proceedings. While the filing is a material event, the relatively small claim amount suggests it is a commercial dispute rather than a sign of systemic financial distress.
Key Highlights
Insolvency petition filed under Section 9 of the IBC at NCLT Ahmedabad.
Claim amount involved is approximately ₹2.63 Crores.
Non-payment attributed to quality issues in goods/services provided by the petitioner.
Next hearing date for the matter is scheduled for April 20, 2026.
Management expects an out-of-court settlement with no long-term impact on operations.
👀 What to Watch
Investors should monitor the situation until the next hearing on April 20, 2026, to ensure a settlement is reached. Given the small claim size relative to Heranba's scale, this is likely a tactical legal move by a creditor rather than a solvency crisis.
IBC Insolvency Application Filed Against Heranba Subsidiary Over Rs 93.90 Lakh Claim
Haresh Petrochem Private Limited has filed an insolvency petition under the IBC against Heranba Organics Private Limited, a 100% subsidiary of Heranba Industries. The initial claim was approximately Rs 1.70 Crores, which has been reduced to an outstanding balance of Rs 93.90 Lakhs following part payments. The company states the remaining balance is withheld due to quality disputes regarding the supplied goods. Management expects to settle the matter amicably outside the NCLT framework once the quality issues are addressed.
Key Highlights
Insolvency application filed under Section 9 of IBC against 100% subsidiary Heranba Organics.
Total claim amount reduced from Rs 1.70 Crores to an outstanding balance of Rs 93.90 Lakhs.
Payment withheld by the subsidiary due to unresolved quality issues with the petitioner's supplies.
Management expects an out-of-court settlement and does not anticipate long-term material impact.
👀 What to Watch
Monitor the progress of the NCLT proceedings to ensure the settlement is reached as planned. While the claim amount is small, any escalation in insolvency proceedings for a subsidiary requires caution.
Heranba Q3: Consolidated Net Loss Widens to ₹23.29 Cr; Standalone Profit at ₹9.32 Cr
Heranba Industries reported a weak set of consolidated numbers for Q3 FY26, with the net loss widening to ₹23.29 crore from a loss of ₹10.37 crore in the same quarter last year. Consolidated revenue from operations declined to ₹305.17 crore, down from ₹341.29 crore year-on-year. While standalone operations turned profitable at ₹9.32 crore compared to a loss last year, the consolidated performance was dragged down by higher finance costs and depreciation. The company also announced the appointment of ZMAS and Associates as the new Internal Auditor.
Key Highlights
Consolidated revenue from operations fell to ₹305.17 crore in Q3 FY26 from ₹341.29 crore in Q3 FY25.
Consolidated net loss widened significantly to ₹23.29 crore versus a loss of ₹10.37 crore YoY.
Standalone profit stood at ₹9.32 crore, a recovery from a standalone loss of ₹9.12 crore in the previous year's quarter.
Consolidated finance costs doubled to ₹12.39 crore from ₹6.15 crore in the year-ago period.
Consolidated depreciation and amortisation expenses rose sharply to ₹25.67 crore from ₹14.03 crore YoY.
👀 What to Watch
Investors should exercise caution as widening consolidated losses and rising finance costs indicate significant pressure on the bottom line. The divergence between standalone profit and consolidated loss suggests underperformance in subsidiary operations that requires further scrutiny.
Heranba Q3 Results: Standalone Profit of ₹9.32 Cr; Consolidated Net Loss Widens to ₹23.29 Cr
Heranba Industries reported a mixed Q3 FY26, with standalone operations turning profitable at ₹9.32 crore despite a 9.4% YoY revenue dip to ₹306.55 crore. However, the consolidated picture is concerning as net losses widened to ₹23.29 crore from ₹10.37 crore YoY. This deterioration is largely driven by a sharp spike in consolidated depreciation (₹25.67 crore vs ₹14.03 crore) and finance costs (₹12.39 crore vs ₹6.15 crore). The company also announced the appointment of ZMAS and Associates as internal auditors.
Key Highlights
Standalone Net Profit of ₹9.32 crore vs a loss of ₹9.12 crore in Q3 FY25.
Consolidated Net Loss widened significantly to ₹23.29 crore from ₹10.37 crore YoY.
Consolidated Finance Costs surged 101% YoY to ₹12.39 crore.
Consolidated Depreciation and Amortization increased by 83% YoY to ₹25.67 crore.
Nine-month consolidated revenue showed growth at ₹1,235.58 crore vs ₹1,074.96 crore YoY.
👀 What to Watch
The widening consolidated loss despite standalone profitability suggests significant drag from subsidiaries or new capital expenditures not yet yielding returns. Investors should wait for management commentary on margin recovery and debt levels before taking new positions.
Heranba Subsidiary to Incorporate UAE Unit with INR 2 Crore Initial Investment
Heranba Industries Limited has announced that its wholly-owned subsidiary, Mikusu India Private Limited, will establish a new 100% subsidiary in the United Arab Emirates. The new entity will focus on the agro-chemical business, specifically pesticides, insecticides, and herbicides. An initial cash investment of up to INR 2.00 crores is planned for this expansion. This strategic move aims to enhance the company's global footprint and distribution capabilities in the Middle East.
Key Highlights
Board of Mikusu India Private Limited approved the 100% WOS in UAE on January 14, 2026.
Proposed initial investment in the UAE subsidiary is up to INR 2.00 crores in cash.
The entity will deal in chemical products including fungicides, weedicides, and pesticides.
RBI approval will be required for the remittance of Outward Direct Investment (ODI) post-inception.
👀 What to Watch
Investors should view this as a positive step toward international market penetration. Monitor the progress of the UAE subsidiary's incorporation and its eventual contribution to the company's export revenue.
